These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 20721825)

  • 1. Therapeutic bispecific antibodies: The selection of stable single-chain fragments to overcome engineering obstacles.
    Mabry R; Snavely M
    IDrugs; 2010 Aug; 13(8):543-9. PubMed ID: 20721825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
    Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
    Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secretion from bacterial versus mammalian cells yields a recombinant scFv with variable folding properties.
    Vendel MC; Favis M; Snyder WB; Huang F; Capili AD; Dong J; Glaser SM; Miller BR; Demarest SJ
    Arch Biochem Biophys; 2012 Oct; 526(2):188-93. PubMed ID: 22230329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody therapeutics, antibody engineering, and the merits of protein stability.
    Demarest SJ; Glaser SM
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab-based bispecific antibody formats with robust biophysical properties and biological activity.
    Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ
    MAbs; 2015; 7(3):470-82. PubMed ID: 25774965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion.
    Lu D; Zhu Z
    Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocell targeting using engineered bispecific antibodies.
    Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
    MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
    Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
    Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTbetaR.
    Michaelson JS; Demarest SJ; Miller B; Amatucci A; Snyder WB; Wu X; Huang F; Phan S; Gao S; Doern A; Farrington GK; Lugovskoy A; Joseph I; Bailly V; Wang X; Garber E; Browning J; Glaser SM
    MAbs; 2009; 1(2):128-41. PubMed ID: 20061822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant approaches to IgG-like bispecific antibodies.
    Marvin JS; Zhu Z
    Acta Pharmacol Sin; 2005 Jun; 26(6):649-58. PubMed ID: 15916729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of the Fc fusion format to generate tag-free bi-specific diabodies.
    Asano R; Ikoma K; Kawaguchi H; Ishiyama Y; Nakanishi T; Umetsu M; Hayashi H; Katayose Y; Unno M; Kudo T; Kumagai I
    FEBS J; 2010 Jan; 277(2):477-87. PubMed ID: 20015073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression, engineering and characterization of the tumor-targeting heterodimeric immunocytokine F8-IL12.
    Sommavilla R; Pasche N; Trachsel E; Giovannoni L; Roesli C; Villa A; Neri D; Kaspar M
    Protein Eng Des Sel; 2010 Aug; 23(8):653-61. PubMed ID: 20551083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
    Vincent KJ; Zurini M
    Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential therapeutic roles for antibody mixtures.
    Raju TS; Strohl WR
    Expert Opin Biol Ther; 2013 Oct; 13(10):1347-52. PubMed ID: 23886377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.
    Byrne H; Conroy PJ; Whisstock JC; O'Kennedy RJ
    Trends Biotechnol; 2013 Nov; 31(11):621-32. PubMed ID: 24094861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.